The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

With fresh billions unlocked in the 2026 U.S. budget and mission‑driven family offices recalibrating after a “nuclear winter, ...

Damian Garde joins Allison, Adam, and Elaine to discuss his article about Boris Nikolic, a well-connected biotech investor ...

The biotechnology industry has long been characterized by astronomical development costs and lengthy timelines that can stretch into decades. Traditional drug development programs routinely require ...

Makary pointed to three bottlenecks: hospital contracting; ethical reviews and approvals; and the Investigational New Drug ...

Drug Development Insights: What New Industry Data Reveals for 2026, Upcoming Webinar Hosted by Xtalks In this free webinar, learn how today's industry trends and challenges are shaping drug ...

In 2025 it seemed the only certainty for biotech was more uncertainty. Biotech leaders conducted business as usual against ...

DUBLIN--(BUSINESS WIRE)--The "AI in Biotechnology: Global Markets" report has been added to ResearchAndMarkets.com's offering. The global market for AI in biotechnology was valued at $3.8 billion in ...

Edesa Biotech, Inc. has announced its financial results for the first half of 2025, highlighting a $15 million equity financing aimed at advancing its vitiligo drug candidate, EB06, an anti-CXCL10 ...

Ron, managing partner at FreeMind Group, and Ravi Kiron, managing director at Biopharma Strategy Advisors. We'll be speaking ...

Xenon Pharmaceuticals said its treatment for a common type of seizure disorder significantly reduced the frequency of those seizures compared to a placebo.